mosunetuzumab Lunsumio
Selected indexed studies
- Mosunetuzumab: First Approval. (Drugs, 2022) [PMID:35947358]
- Mosunetuzumab (Lunsumio) for follicular lymphoma. (Med Lett Drugs Ther, 2023) [PMID:36877285]
- Mosunetuzumab. (, 2006) [PMID:36701508]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mosunetuzumab. (2006) pubmed
- Mosunetuzumab: First Approval. (2022) pubmed
- Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. (2023) pubmed
- Mosunetuzumab (Lunsumio) for follicular lymphoma. (2023) pubmed
- Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL). (2023) pubmed
- Antibodies to watch in 2023. (2023) pubmed
- Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review. (2024) pubmed